[D-penicillamine-induced IgA deficiency in the therapy of Wilson's disease].
Serum IgA deficiency was first noted in a 10 year old boy 8 months after the onset of D-penicillamine therapy. Special immunological examinations revealed a deficiency of the secretory component of IgA while cellular functions of T- and B-lymphocytes were normal. The patient showed discrete clinical signs compatible with IgA deficiency. Regular control of patients with Morbus Wilson and D-penicillamine treatment should include measurement of serum immunoglobulin levels.
Ibel
H
H
Klinik mit Poliklinik für Kinder und Jugendliche, Universität Erlangen-Nürnberg.
Feist
D
D
Endres
W
W
Belohradsky
B H
BH
D000361:Agammaglobulinemia / Q000139:chemically induced* / Q000276:immunology; D002648:Child; D006527:Hepatolenticular Degeneration / Q000188:drug therapy*; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000172:deficiency*; D008297:Male; D010396:Penicillamine / Q000009:adverse effects* / Q000627:therapeutic use
D007071:Immunoglobulin A, Secretory; D010396:Penicillamine
D-Penicillamin-induzierter IgA-Mangel bei der Therapie der Wilsonschen Erkrankung.